Loading...
XHKG
2096
Market cap2.77bUSD
Apr 03, Last price  
8.66HKD
1D
3.10%
1Q
25.33%
IPO
-21.27%
Name

Simcere Pharmaceutical Group Ltd

Chart & Performance

D1W1MN
P/E
28.21
P/S
3.05
EPS
0.29
Div Yield, %
2.03%
Shrs. gr., 5y
0.02%
Rev. gr., 5y
7.92%
Revenues
6.61b
+4.57%
2,082,966,0003,867,908,0004,514,204,0005,036,658,0004,508,720,0004,999,718,0006,319,096,0006,607,805,000
Net income
715m
-23.22%
56,957,000350,409,000733,687,0001,003,624,000669,534,0001,507,096,000930,868,000714,761,000
CFO
151m
-88.85%
313,578,000939,076,000775,817,000772,803,00096,731,000-201,970,0001,354,712,000151,048,000
Dividend
Jun 18, 20250.17129 HKD/sh
Earnings
Aug 19, 2025

Profile

Simcere Pharmaceutical Group Limited engages in the research, development, manufacture, and sale of pharmaceutical products for distributors and pharmacy chains and other pharmaceutical manufacturers in China. It focusses on various therapeutic areas, including oncology, central nervous system, autoimmune, anti-infection, cardiovascular, and others. The company's principal products include Sanbexin, an edaravone and dexborneol concentrated solution for injection; Endostar, a recombinant human endostatin injection; ENWEIDA, an envafolimab injection; Softan, a rosuvastatin calcium tablet; ZAILIN, an amoxicillin granules/dispersible tablet/capsule; Iremod, an iguratimod tablet; Antine, a diclofenac sodium sustained release capsule/gel; and Orencia, an abatacept injection. It also offers promotion services for pharmaceutical products. Simcere Pharmaceutical Group Limited has a strategic regional licensing partnership with Vivoryon Therapeutics N.V. to develop and commercialize medicines targeting the neurotoxicity amyloid protein N3pE (pGlu-Aß) to treat Alzheimer's disease. The company was founded in 1995 and is headquartered in Nanjing, China.
URL
http://www.simcere.com/
IPO date
Oct 27, 2020
Employees
7,661
Domiciled in
CN
Incorporated in
HK

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑12
Income
Revenues
6,607,805
4.57%
6,319,096
26.39%
Cost of revenue
6,031,005
5,897,087
Unusual Expense (Income)
NOPBT
576,800
422,009
NOPBT Margin
8.73%
6.68%
Operating Taxes
26,088
(40,478)
Tax Rate
4.52%
NOPAT
550,712
462,487
Net income
714,761
-23.22%
930,868
-38.23%
Dividends
(419,218)
(391,296)
Dividend yield
2.39%
1.29%
Proceeds from repurchase of equity
(289,073)
BB yield
1.65%
Debt
Debt current
1,094,981
1,350,823
Long-term debt
542,488
370,598
Deferred revenue
403,350
Other long-term liabilities
610,788
Net debt
(1,960,672)
(3,456,269)
Cash flow
Cash from operating activities
151,048
1,354,712
CAPEX
(483,182)
(678,005)
Cash from investing activities
1,087,807
68,306
Cash from financing activities
(894,834)
(753,681)
FCF
(495,748)
338,362
Balance
Cash
2,018,299
2,621,826
Long term investments
1,579,842
2,555,864
Excess cash
3,267,751
4,861,735
Stockholders' equity
7,222,736
6,368,435
Invested Capital
5,994,997
4,046,761
ROIC
10.97%
10.17%
ROCE
6.23%
4.68%
EV
Common stock shares outstanding
2,608,534
2,620,376
Price
6.73
-42.08%
11.62
33.26%
Market cap
17,555,433
-42.34%
30,448,768
33.72%
EV
15,594,761
27,008,561
EBITDA
886,394
704,937
EV/EBITDA
17.59
38.31
Interest
34,568
34,408
Interest/NOPBT
5.99%
8.15%